| Autor: |
Grizzi G; Oncology Unit, ASST Cremona, 26100 Cremona, Italy., Salati M; Department of Oncology and Hematology, University Hospital of Modena, 41124 Modena, Italy., Bonomi M; Oncology Unit, ASST Cremona, 26100 Cremona, Italy., Ratti M; Oncology Unit, ASST Cremona, 26100 Cremona, Italy., Holladay L; Anne Burnett Marion School of Medicine, Texas Christian University, Fort Worth, TX 76129, USA., De Grandis MC; Oncology Unit 1, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy., Spada D; Oncology Unit, ASST Cremona, 26100 Cremona, Italy., Baiocchi GL; Department of Surgery, ASST Cremona, 26100 Cremona, Italy., Ghidini M; Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy. |
| Abstrakt: |
Gastric cancer (GC) is still one of the most aggressive cancers with a few targetable alterations and a dismal prognosis. A liquid biopsy allows for identifying and analyzing the DNA released from tumor cells into the bloodstream. Compared to tissue-based biopsy, liquid biopsy is less invasive, requires fewer samples, and can be repeated over time in order to longitudinally monitor tumor burden and molecular changes. Circulating tumor DNA (ctDNA) has been recognized to have a prognostic role in all the disease stages of GC. The aim of this article is to review the current and future applications of ctDNA in gastric adenocarcinoma, in particular, with respect to early diagnosis, the detection of minimal residual disease (MRD) following curative surgery, and in the advanced disease setting for treatment decision choice and therapeutic monitoring. Although liquid biopsies have shown potentiality, pre-analytical and analytical steps must be standardized and validated to ensure the reproducibility and standardization of the procedures and data analysis methods. Further research is needed to allow the use of liquid biopsy in everyday clinical practice. |
